News and Announcements
Frazis Capital Strategy Update – January 2021
- Published January 28, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Watch the video below to listen to hear Frazis Capital’s strategy update.
In the video, Michael Frazis talks about how to survive huge market swings, the current investment strategy of Frazis and more.
About Frazis Capital
The Frazis Fund invests in leading innovative growth companies around the world, specifically we focus on companies with;
- Intense customer love
- Exponential revenue growth, and
- Genuine market leadership.
Our team conducts detailed research into highly innovative areas and identifies the industries driving global growth, such as software, the life sciences, renewable energy, and the technology sector more broadly. Our team then undertakes a deep analysis to identify the market leaders and category creators with the strongest industry tailwinds, and the most robust competitive positioning.
The Fund has broad discretion to invest across various liquid asset classes.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
